Glaxosmithkline Pharmaceuticals (GLAXO) Share Price Fall Streak Continues for Second Straight Session

Glaxosmithkline Pharmaceuticals Share Price Fall Streak is the focus today as the stock traded lower in its second straight session. The latest traded price stood at Rs 2,573.10, down 2.28% from the previous session, and the cumulative fall across the streak now stands at 6.71%. According to Univest data, the price pattern is confirmed, but no company-specific catalyst is established.

Glaxosmithkline Pharmaceuticals Share Price Fall Streak matters because a second lower session changes the reading from a one-off decline to a short run of weakness. The company’s market capitalisation stood at Rs 46,723.88 crore, which places the move in a large-cap name rather than a smaller traded counter. For readers tracking Glaxosmithkline Pharmaceuticals Share Price Today, the key point is that the streak, not a single session, is now the headline. According to latest Univest figures, the latest move should be read alongside valuation, sector positioning and peer comparison rather than as an isolated print.

Glaxosmithkline Pharmaceuticals (GLAXO) Share Price Fall Streak: Consecutive Decline Analysis

Metric	Value
Current Price	Rs 2,573.1
Previous Close	Rs 2,633.25
Today's Move	-Rs 60.15 (-2.28%)
Open	Rs 2,640
High	Rs 2,640
Low	Rs 2,569.7
Market Capitalisation	Rs 46,723.88 crore

Glaxosmithkline Pharmaceuticals Share Price Fall Streak carried into the session with the stock opening at Rs 2,640 and moving between Rs 2,640 and Rs 2,569.70 during the day. The latest traded price of Rs 2,573.10 was below the previous close of Rs 2,633.25 by Rs 60.15, matching a 2.28% decline. The day’s low sat very close to the latest traded level, which shows that Glaxosmithkline Pharmaceuticals Share Price Today was trading near the lower end of the range at the time captured by Univest data.

The market capitalisation of Rs 46,723.88 crore keeps the company in the large-cap category, which is useful context when reading a second straight session of decline. The range did not stretch above the open, as the day high was Rs 2,640, the same as the opening print. For Glaxosmithkline Pharmaceuticals Share Price Fall Streak, the visible takeaway is straightforward: the stock is lower again, the streak has extended, and the move is best assessed alongside valuation and sector benchmarks rather than in isolation.

What the Consecutive Declines Show

Glaxosmithkline Pharmaceuticals Share Price Fall Streak now spans a second straight session, and the cumulative decline of 6.71% from Rs 2,758.10 provides the broader read. That cumulative figure matters more than the latest daily move because it shows how the price has shifted across two sessions instead of only one. According to Univest data, the streak confirms a pattern of consecutive lower prints, while still giving no company-specific cause for the move.

For readers following Glaxosmithkline Pharmaceuticals Share Price Fall Streak, the distinction is important: a two-session run can change how the market reads the stock’s near-term price path, even when the business data itself has not changed over the same short window. The price event is therefore best understood as a streak of lower sessions, not as a separate fundamental shift. That makes the next sections on valuation, sector context and peers especially relevant to the current reading of Glaxosmithkline Pharmaceuticals Share Price Fall Streak.

Glaxosmithkline Pharmaceuticals (GLAXO) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 46,723.88 crore
P/E Ratio	41.76x
P/B Ratio	17.7x
ROE	48.76%
ROCE	66.79%
EPS	Rs 63.05
Book Value Per Share	Rs 148.77
Dividend Yield	2.16%

Glaxosmithkline Pharmaceuticals (GLAXO) fundamental metrics show P/E 41.76x, P/B 17.7x, ROE 48.76%, ROCE 66.79%. These figures provide context only and are not a buy or sell signal.

Glaxosmithkline Pharmaceuticals has a market capitalisation of Rs 46,723.88 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 41.76x, P/B at 17.7x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 48.76% and ROCE of 66.79%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 63.05, book value per share of Rs 148.77, dividend yield of 2.16%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.87x, median ROE of 11.61%, median ROCE of 13.46%. Taken together, they outline the fundamentals rather than a view on the stock.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	41.76x
Benchmark Median P/E	31.87x
Benchmark Average P/E	48.48x
Benchmark P/E Range	3.58x to 708.87x
Company P/B Ratio	17.7x
Benchmark Median P/B	2.98x
Benchmark Average P/B	4.31x
Company ROE	48.76%
Benchmark Median ROE	11.61%
Benchmark Average ROE	10.59%
Company ROCE	66.79%
Benchmark Median ROCE	13.46%
Benchmark Average ROCE	13.36%
Company Market Capitalisation	Rs 46,723.88 crore
Benchmark Median Market Cap	Rs 854.81 crore
Benchmark Average Market Cap	Rs 14,121.7 crore

Glaxosmithkline Pharmaceuticals (GLAXO) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.

Glaxosmithkline Pharmaceuticals (GLAXO) has a P/E ratio of 41.76x, which is above the benchmark median of 31.87x, a difference of +31.03%. On its own, the P/E gap is a valuation reference point, not a trading call.

Glaxosmithkline Pharmaceuticals (GLAXO) has a ROE of 48.76%, which is above the benchmark median of 11.61%, a difference of +319.98%. Glaxosmithkline Pharmaceuticals (GLAXO) has a ROCE of 66.79%, which is above the benchmark median of 13.46%, a difference of +396.21%.

Track stocks among today's decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries	SUNPHARMA	4,32,120.23	35.37	4.95	14.85	19.11
Divi's Laboratories	DIVISLAB	2,53,389.76	86.95	14.4	16.19	21.51
Torrent Pharmaceuticals	TORNTPHARM	1,81,739.76	82.14	19.96	26.76	19.27
Zydus Lifesciences	ZYDUSLIFE	1,15,710.44	25.51	4.27	19.69	21.39
Laurus Labs	LAURUSLABS	1,10,980.13	101.55	19.69	18.31	18.2

Glaxosmithkline Pharmaceuticals (GLAXO) has a P/E ratio of 41.76x compared with the displayed peer median of 82.14x. This peer read is a relative benchmark rather than a trading signal. Its ROE of 48.76% compares with a peer median of 18.31% across the companies shown in the table. ROCE stood at 66.79% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Glaxosmithkline Pharmaceuticals (GLAXO) has a market capitalisation of Rs 46,723.88 crore. All 5 peers shown have a larger market capitalisation.

Why Investors Are Watching Glaxosmithkline Pharmaceuticals

• Glaxosmithkline Pharmaceuticals Share Price Fall Streak is now in a second straight session, so the short-run price pattern is the main market focus.
• The latest traded price of Rs 2,573.10 is below the previous close of Rs 2,633.25, with a 2.28% decline in the session captured by Univest data.
• Large-cap status and a market capitalisation of Rs 46,723.88 crore keep the stock in a meaningful bracket for healthcare comparison.
• P/E of 41.76 and P/B of 17.7 still signal a premium valuation versus the industry median, even after the fall.
• ROE of 48.76% and ROCE of 66.79% remain notably above the healthcare benchmark and peer set shown here.

About Glaxosmithkline Pharmaceuticals

Glaxosmithkline Pharmaceuticals operates in Healthcare and the Pharmaceuticals & Drugs industry. The company is read here through the lens of Glaxosmithkline Pharmaceuticals Share Price Fall Streak, so the business context that matters most is how a large-cap pharmaceutical name with premium returns is being priced in the market. Readers following Glaxosmithkline Pharmaceuticals Share Price Today can treat the business as a healthcare company whose valuation is being measured against other listed drug makers. The company’s earnings and book-value metrics provide the backdrop for interpreting the streak, while the sector and peer set define how unusual the current price move is.

Track Glaxosmithkline Pharmaceuticals Share Price on Univest

Use Glaxosmithkline Pharmaceuticals (GLAXO) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners and related market analysis.

Track Glaxosmithkline Pharmaceuticals Share Price on Univest for live price updates, valuation ratios, 52-week levels and broader market insights. The same page also helps users follow Glaxosmithkline Pharmaceuticals Share Price Fall Streak alongside key fundamentals, sector context and peer comparison in one place. That makes it easier to monitor how today’s move fits into the broader stock picture without losing sight of the company’s healthcare backdrop.

Frequently Asked Questions

Why is Glaxosmithkline Pharmaceuticals Share Price falling today?

Ans. Glaxosmithkline Pharmaceuticals Share Price is lower in a second straight session, with the latest traded price at Rs 2,573.10 and the cumulative streak down 6.71%. According to Univest data, the pattern is confirmed, but no company-specific cause is established.

What is the latest Glaxosmithkline Pharmaceuticals Share Price?

Ans. The latest traded price is Rs 2,573.10 as of 08 October 2026 at 11:23:13 AM IST. It was below the previous close of Rs 2,633.25 and reflected a 2.28% decline in the captured session.

How much has Glaxosmithkline Pharmaceuticals Share Price fallen in the streak?

Ans. The cumulative decline across the second straight session streak is 6.71%, from a streak start base price of Rs 2,758.10. That makes the move more than a single-day print and places the streak in clear focus.

What do the current valuation ratios show for Glaxosmithkline Pharmaceuticals Share Price?

Ans. Glaxosmithkline Pharmaceuticals Share Price is supported by a P/E of 41.76 and a P/B of 17.7. Those are premium levels versus the healthcare benchmark median, even after the latest decline.

How do ROE and ROCE look for Glaxosmithkline Pharmaceuticals Share Price?

Ans. ROE stands at 48.76% and ROCE at 66.79%, both well above the industry median shown for the same healthcare peer set. That keeps the return profile strong despite the ongoing Glaxosmithkline Pharmaceuticals Share Price Fall Streak.

What are the book value, EPS and dividend yield for Glaxosmithkline Pharmaceuticals Share Price?

Ans. EPS is Rs 63.05, book value is Rs 148.77 and dividend yield is 2.16%. These figures help explain the earnings and accounting base behind Glaxosmithkline Pharmaceuticals Share Price during the current fall streak.

How does Glaxosmithkline Pharmaceuticals Share Price compare with healthcare peers?

Ans. Glaxosmithkline Pharmaceuticals Share Price has a lower market cap than Sun Pharmaceutical Industries, Divi’s Laboratories and Torrent Pharmaceuticals, but its ROE and ROCE are higher than every listed peer in the comparison set.

What does the sector benchmark say about Glaxosmithkline Pharmaceuticals Share Price?

Ans. The company’s P/E of 41.76 is above the industry median of 31.87 and below the average of 48.48. Its P/B of 17.7 is also far above the industry median, showing a clear premium valuation.

Should investors track Glaxosmithkline Pharmaceuticals Share Price on Univest?

Ans. Yes. Univest lets users track Glaxosmithkline Pharmaceuticals Share Price alongside ratios, market capitalisation, 52-week levels and sector context. That combination helps place the fall streak inside a broader analytical view.